Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 23 May 2025, including: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories Mentioned In This Episode:
- Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle
- How Much Does Biopharma Contribute To The US Economy?
- A Short History Of MASH Deals, Culminating In GSK/Boston Pharma
- ‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra
- Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear
